Study TRX109013, TREXIMA™ (Sumatriptan + Naproxen Sodium) Versus Butalbital-Containing Combination Medications (BCM) for the Acute Treatment of Migraine - Related Studies

Study TRX109013, TREXIMA™ (Sumatriptan + Naproxen Sodium) Versus Butalbital-Containing Combination Medications (BCM) for the Acute Treatment of Migraine

This study is currently recruiting participants.

Study NCT00599157. Last updated on November 19, 2008. Information provided by GlaxoSmithKline

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Migraine

2	Additional conditions recognized in this trial
		Migraine Disorders

3	More general conditions related to this trial
		Brain Diseases
		Central Nervous System Diseases
		Headache Disorders
		Headache Disorders, Primary
		Nervous System Diseases

4	Interventions listed in this trial
		Trexima
		butalbital

5	Additional drug interventions recognized in this trial
		Naproxen
		Sumatriptan

6	More general drug interventions related to this trial
		Analgesics
		Analgesics, Non-Narcotic
		Anti-Inflammatory Agents
		Anti-Inflammatory Agents, Non-Steroidal
		Antirheumatic Agents
		Cardiovascular Agents
		Central Nervous System Agents
		Cyclooxygenase Inhibitors
		Enzyme Inhibitors
		Gout Suppressants
		Molecular Mechanisms of Pharmacological Action
		Neurotransmitter Agents
		Peripheral Nervous System Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Sensory System Agents
		Serotonin Agents
		Serotonin Agonists
		Therapeutic Uses
		Vasoconstrictor Agents

7	Sponsors listed in this trial
		GlaxoSmithKline